Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Adaptive Biotechnologies Prices Public Offering of Stock

Adaptive Biotechnologies Prices Public Offering of Stock

Jan 24, 2020
|
staff reporter

NEW YORK – Immune cell sequencing firm Adaptive Biotechnologies said after the close of the market on Thursday that it is selling 8 million shares of common stock at $26.50 per share.

The firm is selling the shares on behalf of certain investors and will not receive any proceeds from the sale.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Extension Call

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

All Along the Axon

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

For the Accelerator

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

Science Papers Describe New Cas9 Variant, Atlas of Human Metabolism

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

What's Popular?

In Business News

  1. Fosun Long March Gets Chinese Regulatory Approval for Coronavirus MDx Kit

  2. GigaMune Hopes to Offer TCR Screens to Pharmas While Scrambling to Keep Expression Libraries Alive

    Premium

  3. Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

  4. Danaher Prices €1.7 Billion Offering of Senior Notes

  5. AmoyDx, Janssen Research and Development Partner on NGS-Based Companion Diagnostic

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.